Comparison of the renal response of bortezomib-based induction and conventional regimen in multiple myeloma patients with renal failure

Basit Öğe Kaydı
dc.contributor.authorSarici, Ahmet
dc.contributor.authorKaya, Emin
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorBerber, Ilhami
dc.contributor.authorTanrıverdi, Lokman Hekim
dc.contributor.authorBahçecioğlu, Ömer Faruk
dc.contributor.authorGök, Selim
dc.contributor.authorKuku, Irfan
dc.date.accessioned2022-12-06T08:45:33Z
dc.date.available2022-12-06T08:45:33Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim: Vincristine-doxorubicin-dexamethasone (VAD) was the commonly used first-line treatment for multiple myeloma (MM) patients with renal failure before bortezomib entered clinical practice. In this trial, we aimed to compare the effect of VAD and bortezomibcyclophosphamide-dexamethasone (VCD) chemotherapy regimens on improving kidney function in MM patients with renal failure. Materials and Methods: The records of MM patients in our center between January 2010 and February 2020 were retrospectively analyzed. Patients who received VAD or VCD as a first treatment chemotherapy protocol and whose initially estimated glomerular filtration rate (eGFR) was 50 mL/min/1.73 m2and below were included in the study. Patients were divided into two groups according to the chemotherapy regimens they received. Results: Sixty one MM patients (VAD: 26, VCD: 35) were included in the study. No significant difference was found between the VAD and VCD groups when the baseline, 1st and 2nd month eGFRs were compared (p>0.05). Overall renal response rate (at least minor response) in the VCD group at the end of the 1st month were higher than in the VAD group (p=0.002). Also, renal response rate in the VCD group at the end of the 2nd month were higher than in the VAD group (p=0.033). Conclusion: In MM patients with renal insufficiency, overall renal response rates have increased with the use of VCD instead of VAD as a standard induction regimen.en_US
dc.identifier.citationSARİCİ A, KAYA E, ERKURT M, BERBER I, TANRİVERDİ L, BAHCECİOGLU O, GOK S, KUKU I (2021). Comparison of the renal response of bortezomib-based induction and conventional regimen in multiple myeloma patients with renal failure. Annals of Medical Research, 28(10), 1824 - 1829. 10.5455/annalsmedres.2021.01.098en_US
dc.identifier.doi10.5455/annalsmedres.2021.01.098en_US
dc.identifier.endpage1829en_US
dc.identifier.issn2636-7688
dc.identifier.issue10en_US
dc.identifier.startpage1824en_US
dc.identifier.trdizinid482619en_US
dc.identifier.urihttps://doi.org/10.5455/annalsmedres.2021.01.098
dc.identifier.urihttps://hdl.handle.net/11616/85629
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/482619
dc.identifier.volume28en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofAnnals of Medical Researchen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleComparison of the renal response of bortezomib-based induction and conventional regimen in multiple myeloma patients with renal failureen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
document - 2022-12-06T114518.478.pdf
Boyut:
177.03 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu